Get the Stockscreener App
1.43
11.73%
-0.19
After Hours:
1.39
-0.04
-2.80%
Imunon Inc stock is traded at $1.43, with a volume of 1.50M.
It is down -11.73% in the last 24 hours and up +78.75% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
See More
Previous Close:
$1.62
Open:
$1.56
24h Volume:
1.50M
Relative Volume:
0.15
Market Cap:
$29.67M
Revenue:
$500.00K
Net Income/Loss:
$-19.45M
P/E Ratio:
-0.7566
EPS:
-1.89
Net Cash Flow:
$-18.22M
1W Performance:
-2.05%
1M Performance:
+78.75%
6M Performance:
+69.33%
1Y Performance:
+19.67%
1-Day Range:
$1.40
$1.57
1-Week Range:
$1.27
$2.12
52-Week Range:
$0.37
$3.65
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
1.43 | 29.67M | 500.00K | -19.45M | -18.22M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Imunon Inc Stock (IMNN) Latest News
Imunon Inc. appoints new CFO following termination - Investing.com Australia
Imunon Inc. appoints new CFO following termination By Investing.com - Investing.com South Africa
Imunon Appoints Kimberly Graper as Interim CFO - TipRanks
ImunonTerminates CFO David Gaiero's Service Agreement - marketscreener.com
Why Imunon, Inc. (IMNN) Surged Last Week - MSN
Imunon regains Nasdaq compliance with bid price By Investing.com - Investing.com South Africa
Imunon Regains Nasdaq Compliance with Bid Price - TipRanks
Imunon regains Nasdaq compliance with bid price - Investing.com
Imunon (NASDAQ:IMNN) Raised to Sell at Wall Street Zen - Defense World
Top Companies in the NASDAQ by Kalkine Leading Market Performers Today - Kalkine Media
Equities Analysts Offer Predictions for Imunon Q2 Earnings - Defense World
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th - GlobeNewswire
Phase 3 DNA Immunotherapy Developer IMUNON Opens Live Q&A with Investors Next Week - Stock Titan
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer - Yahoo Finance
IMUNON Announces Data Presented at ASCO Reinforces - GlobeNewswire
Imunon announces data from Phase 2 OVATION 2 study on IMNN-001 - TipRanks
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented - GuruFocus
IMNN: Promising Phase 2 Results in Ovarian Cancer Treatment | IMNN Stock News - GuruFocus
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study - Yahoo Finance
Imunon CEO says company ‘has never been stronger’ - TipRanks
IMNN Advances Cancer Treatment with Promising Phase 2 Results | IMNN Stock News - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDA - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS | IMNN Stock News - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS - The Manila Times
Breakthrough Ovarian Cancer Drug Extends Patient Survival by 13 Months in Phase 2 Trial, ASCO Data Shows - Stock Titan
Should You Buy, Sell, or Hold Shopify Stock in June 2025? - The Globe and Mail
IMUNON launches up to $9.75M securities offering - MSN
Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues By Investing.com - Investing.com Canada
Imunon (IMNN) Announces Plans to Offer 22.03 Million Shares | IM - GuruFocus
Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues - Investing.com India
Imunon Faces Nasdaq Delisting Due to Non-Compliance - TipRanks
Public market insider selling at TerraVest Industries (TVK) - The Globe and Mail
Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More - Yahoo Finance
IMUNON’s Stacy Lindborg on the long road to Phase III - The Pharma Letter
IMUNON Closes Up To $9.75 Million Private Placement Priced At-Th - GuruFocus
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Phase 3 Biotech IMUNON Raises $9.75M: Strategic Private Placement Fuels DNA Immunotherapy Development - Stock Titan
Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon By Stocktwits - Investing.com India
Imunon to present translational data in supporting Phase 2 OVATION Study - TipRanks
Imunon (IMNN) Gains Attention with Upcoming ESMO Presentation | - GuruFocus
IMUNON, Inc. to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 - marketscreener.com
IMNN's Immune Biomarker Data to be Highlighted at ESMO 2025 | IM - GuruFocus
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 - The Manila Times
Imunon announces up to $9.75M private placement priced at-the-market - Yahoo Finance
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 | IMNN Stock News - GuruFocus
IMUNON Invited to Present Translational Data in Supporting - GlobeNewswire
Breakthrough Ovarian Cancer Drug Extends Life by 13 Months in Phase 2 Trial: Key Data Coming to ESMO - Stock Titan
Imunon Announces Private Placement Agreement with Investors - TipRanks
3 Penny Stocks to Watch Now, 5/27/25 - TipRanks
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Imunon Inc Stock (IMNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lindborg Stacy | President and CEO |
Aug 15 '24 |
Buy |
0.98 |
25,000 |
24,500 |
264,166 |
| Tardugno Michael H | Executive Chairman of Board |
Aug 15 '24 |
Buy |
1.03 |
25,000 |
25,750 |
353,346 |
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):